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Significance 
Diffuse large B cell lymphoma (DLBCL) is the commonest form of non-Hodgkin 
lymphoma and is incurable in roughly 30% of cases.  Here, we demonstrate addiction of 
both major subtypes of DLBCL to the expression of the transcription factor OCT2 and its 
co-activator OCA-B.  We clarify the role of OCT2 in normal germinal center biology and 
identify the genes and pathways that it regulates in malignant B cells.  Our findings 
suggest that pharmacological agents designed to target OCT2 itself or the OCT2–OCA-B 
interface would be an effective and non-toxic therapeutic strategy in DLBCL.  
Abstract 
The requirement for the B cell transcription factor OCT2 (encoded by Pou2f2) in 
germinal center B cells has proved controversial. Here, we report that germinal center B 
cells are formed normally after depletion of OCT2 in a conditional knockout mouse but 
that their proliferation is reduced and in vivo differentiation to antibody-secreting plasma 
cells is blocked. This led us to examine the role of OCT2 in germinal center derived 
lymphomas.  ShRNA knockdown showed that almost all DLBCL cell lines are addicted 
to the expression of OCT2 and its co-activator OCA-B.  ChIP-Seq and gene expression 
profiling revealed the broad transcriptional program regulated by OCT2 that includes the 
expression of STAT3, IL10, ELL2, XBP1, MYC, TERT and ADA.  Importantly, genetic 
alteration of OCT2 is not a requirement for cellular addiction in DLBCL. However, we 
detected low frequency amplifications of the POU2F2 locus in DLBCL tumor biopsies as 
well as a recurrent mutation of threonine 223 in the DNA binding domain of OCT2.  This 
neomorphic mutation subtly alters the DNA binding preference of OCT2 leading to the 
transactivation of novel target genes including HIF1a and FCRL3. Finally, by introducing 
mutations designed to disrupt the OCT2-OCA-B interface we reveal a requirement for 
this protein-protein interface that might ultimately be exploited therapeutically.  Our 
findings, combined with the predominantly B cell restricted expression of OCT2 and the 
absence of systemic phenotype in our knockout mice, suggest that an OCT2-targeted 
therapeutic strategy would be efficacious in both major subtypes of DLBCL whilst 
avoiding systemic toxicity.  
1
\body 
OCT2, encoded by the gene POU2F2, is a B cell-restricted transcription factor 
that binds to an octamer DNA motif 5’-ATGCAAAT-3’ in the promoters of 
immunoglobulin genes (1). It belongs to the POU domain family of transcription 
factors that uses both a POU homeodomain and a POU-specific domain to bind DNA (2-
4). DNA binding induces a conformational change in the POU domain that permits 
recruitment of the coactivator OCA-B  (also known as BOB-1 or OBF1, encoded by 
POU2AF1), which stabilizes the complex and further enhances transcriptional activation 
(5-10). 
OCT2 and OCA-B are largely restricted in expression to the B cell lineage(1, 7-
10). Although OCT2 was initially thought to direct the B cell-restricted expression of 
immunoglobulin genes by binding to octamer motifs in their promoters, OCT2 knockout 
cell lines were subsequently shown to transcribe immunoglobulin genes normally (11).  
Since mice with germline deletion of Pou2f2 die shortly after birth from an undetermined 
cause (12), fetal liver and bone marrow chimeras have been used to investigate the 
function of OCT2-deficient B cells.  Such mice have reduced B1 and marginal zone B 
cells as well as reduced B cell proliferation and immunoglobulin secretion when 
stimulated in vitro (12, 13).  The role of OCT2 in antigen-dependent germinal center 
responses is controversial, with one study finding a defect in the germinal center response 
to NP-OVA immunization (14) and another reporting normal germinal center formation 
after influenza challenge (15).  OCA-B deficient mice have normal B cell development 
but are unable to mount a germinal center response (16-18). Thus, current evidence 
suggests important functions for OCT2 and OCA-B in the later stages of B cell 
differentiation, but the precise role, if any, for OCT2 in the germinal center reaction is 
unclear. 
Germinal centers form when a mature B cell encounters antigen in the context of 
CD4 T cell help, and are characterized by intense B cell proliferation and hypermutation 
of immunoglobulin genes (19). B cells with improved affinity for the immunizing antigen 
as a result of immunoglobulin hypermutation are selected and eventually differentiate 
into either memory B cells or long-lived plasma cells.  Diffuse large B cell lymphoma 
(DLBCL), the most common type of non-Hodgkin lymphoma, is derived from B cells 
that have transited the germinal center (19).  The germinal center B cell-like (GCB) 
subtype of DLBCL retains expression of germinal center B cell-restricted genes whereas 
the activated B cell-like (ABC) DLBCL subtype appears to be derived from post-
germinal center, plasmablastic cells (20). Both OCT2 and OCA-B are highly expressed in 
normal germinal center B cells and in almost all cases of DLBCL (21, 22). A role for 
OCA-B in DLBCL was proposed based on the identification of a DLBCL-specific super-
enhancer near the OCA-B promoter, but this study did not investigate whether OCA-B 
acts by binding to OCT2 or to the related and ubiquitously expressed POU domain factor 
OCT1 (23).  One study of follicular lymphoma described apparent loss-of-function 
mutations in POU2F2, leading to the suggestion that OCT2 may prevent the formation of 
lymphomas (24).  In the present study, we set out to clarify the role of OCT2 in normal 
germinal center reactions and to determine whether OCT2 acts to promote or restrain the 





Abnormal germinal center function and plasma cell differentiation in OCT2-
deficient mice. We generated conditional Pou2f2 knockout mice from targeted 
embryonic stem cells created by the European Mouse Knockout Consortium.  Lox P sites 
placed on either side of exons 8-11 ensured deletion of the entire POU domain (Fig. 
S1A).  Pou2f2fl/fl mice were crossed first to FLPE recombinase mice (25) to excise the 
neomycin cassette, and then to ERT2-Cre mice in which the Cre recombinase is 
tamoxifen-inducible (26).  We confirmed correct gene targeting by Southern blotting 
(Fig. S1B-D) and observed efficient Cre-mediated deletion in germinal center B cells and 
in splenic B cells (Fig. S1E,F).  Cre-mediated deletion was associated with persistence of 
a Pou2f2 transcript and the production of an unstable protein that lacked exons 8-11 (Fig. 
S1F,G).  Homozygous deletion of Pou2f2 was not associated with any sign of ill health 
or altered behavior in mice observed for more than two months after deletion. 
Heterozygous floxed  (Pou2f2fl/wt), Cre-expressing mice were used as controls. 
Seven days after immunization with sheep red blood cells, the numbers of splenic 
B cells, T cells and germinal center B cells were normal, with no difference in the 
proportion of germinal center light zone (centrocyte) and dark zone (centroblast) cells  
(Fig. 1A & Fig. S2A,B).  Similarly, when immunized with the thymus-dependent 
immunogen NP-KLH, knockout mice had normal numbers of germinal center B cells 
(Fig. S2B).  However, the function of the germinal center B cells in knockout animals 
was not normal in that their cell cycle progression was reduced at 14 days after 
immunization with NP-KLH, as assessed by incorporation of 5-ethynyl-2’-deoxyuridine 
(EDU) (Fig. 1B & Fig. S2C).  Furthermore, serum antigen-specific immunoglobulin 
levels were reduced in knockout animals after immunization with NP-KLH (Fig. 1C).  
By day 28, NP-specific IgM, total NP-specific IgG1 and high affinity NP-specific IgG1 
levels were reduced by 5.5-, 10.6- and 61-fold, respectively.  Moreover, NP-specific 
antibody-secreting cells were almost absent in both spleen and bone marrow when 
measured by ELISpot assays 28 days after immunization (Fig. 1D & Fig. S2D).  In 
contrast, normal numbers of memory B cells (Gr1–, CD11d–, IgM–, IgD–, CD138–, NP+, 
IgG1+, CD38+) were present 28 days after immunization (Fig. S2E), and were able to 
expand normally when mice were rechallenged with NP-KLH 30 days after primary 
immunization  (Fig. 1E & Fig. S2F).  However, OCT2-deficient mice were unable to 
produce immunoglobulin in response to secondary immunization (Fig. S2G). Thus, while 
OCT2-deficient mice were able to initiate germinal center formation normally and 
produce normal numbers of memory B cells, the proliferation of B cells within the 
germinal center was reduced and the production of antibody-secreting plasma cells was 
blocked. 
 
DLBCL cell lines are addicted to expression of both OCT2 and OCA-B. Because of 
the germinal center phenotype in Pou2F2 knockout mice, we examined the dependence 
of human lymphoma cell lines on OCT2 by RNA interference.  Small hairpin RNA 
(shRNA)-mediated knockdown of OCT2 expression was toxic for most DLBCL cell lines 
tested, but not for T cell, Hodgkin, or mantle cell lymphoma lines (Fig. S3A).  In a larger 
panel of cell lines, knockdown of OCT2 was confirmed to be essential in both the ABC 
and GCB DLBCL lines, but not in control T cell lines (Fig. 2A). A similar spectrum of 
toxicity was observed using a second, independent OCT2 shRNA (Fig. S3B), and the 
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toxicity of both shRNAs could be reversed by ectopic expression of OCT2 (Fig. S3C).  
OCT2-depleted cells showed both increased apoptotic cell death, as measured by 
cleavage of caspase 3 and PARP, and reduced cell cycle progression, with an increase in 
G1 phase cells (Fig. S3D,E).  Similarly, knockdown of OCA-B was toxic for all ABC 
and GCB DLBCL cell lines tested, but not T cell lines (Fig. 2B), demonstrating the 
essential role of OCT2 and OCA-B in both common subtypes of DLBCL. 
 
OCT2 and OCA-B bind an overlapping repertoire of genes.  To identify gene targets 
of OCT2 and OCA-B, we performed genome-wide chromatin immunoprecipitation 
analysis (ChIP-Seq) in the HBL1 ABC DLBCL line. Both OCT2 and OCA-B bound a 
large number of genomic sites, with 29,208 and 28,376 binding peaks, respectively.  
These were enriched in promoter-proximal regions: 38% of OCT2 peaks and 34% of 
OCA-B peaks were located within a window from 15 kb upstream to 2 kb downstream of 
a transcriptional start site (TSS) (Fig. 3A). Analysis of promoter peaks revealed OCT2 
and OCA-B interaction with an overlapping repertoire of protein-coding genes (Fig. 3B).  
OCT2 peaks frequently coincided with OCA-B peaks, with their intersection increasing 
as a function of peak size.   Among the 1000 largest OCA-B peaks, almost all coincided 
with OCT2 binding.  By contrast, OCT2 was able to bind DNA as an isolated factor, with 
35% of OCT2 binding regions lacking OCA-B interaction. Using the DNA motif 
discovery program MEME (27), the most strongly enriched motif within both OCT2 and 
OCA-B peak regions was the octamer 5’-ATGCAAAT-3’  (Fig. 3D).  A slightly altered 
motif, 5'-ATGCATAT-3', was enriched at sites binding OCT2 in isolation and may allow 
for a partially overlapping palindromic motif similar to the MORE sequence identified 
for OCT1 binding that precludes OCA-B binding (28). No octamer-related sequence was 
identified within OCA-B peaks lacking OCT2 binding.  The octamer motif was found 
with increasing frequency as a function of OCA-B peak size, being present in 80% of the 
largest OCA-B peaks.  In contrast, in 50% of the largest OCT2 peaks, no octamer motif 
was present, suggesting that OCT2 may be recruited to DNA through an association with 
other, as yet unidentified, DNA-binding factors (Fig. 3E).  Figure 3F shows 
representative OCT2 and OCA-B binding profiles. 
 
OCT2 and OCA-B regulate a broad program of B cell gene expression.  To identify 
genes whose expression depends on OCT2 and OCA-B, we performed gene expression 
profiling after shRNA-mediated knockdown of these factors in 3 ABC and 2 GCB 
DLBCL lines.  For each cell line we generated a list of genes whose expression decreased 
significantly following knockdown of OCT2 and/or OCA-B, and examined these lists for 
overlap with gene expression signatures generated from normal and malignant immune 
cells (Table S1) (29).  Signatures enriched in three or more cell lines are shown in Table 
S1 and include signatures of B cell transcription factor target genes (IRF4, NF-κB, 
STAT3, TCF3), signatures of oncogenic signaling pathways (MYD88, JAK), and 
signatures of B cell differentiation. We generated an “OCT2_Common_UP” signature 
comprised of genes changing in expression in 2 or more cell lines (Fig. S4). The genes in 
this signature with OCT2 peaks in their promoter regions were defined as OCT2 direct 
target genes. OCT2 direct target genes that belong to functionally related signatures 
(Table S1) are summarized in Figure 4A, with those that have overlapping OCT2 and 
OCA-B ChIP-seq peaks highlighted in red. 
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Of particular interest was the regulation of genes that have established roles in 
germinal center biology, plasma cell differentiation or lymphomagenesis, including 
CD22, EBF1, ELL2, XBP1, MYC, TERT, ADA, IL10 and STAT3.  For most of the 
enriched signatures that reflect the action of transcription factors or signaling regulators, 
OCT2 did not influence the expression of the regulatory factor itself but rather influenced 
the expression of its downstream target genes.  An exception is the regulation of 
JAK/STAT3 signatures (Fig. S5A&B), which appeared to be due to decreased expression 
of IL10 and STAT3 in the absence of OCT2, as confirmed by quantitative PCR (qPCR), 
ELISA and immunoblot analysis (Fig. 4B, C, D).  Direct binding of OCT2 to the STAT3 
promoter was confirmed by ChIP  (Fig. S5C).  We observed a significant correlation 
between OCT2 and STAT3 mRNA levels in both ABC and GCB DLBCL tumors 
profiled by RNA sequencing (RNA-seq) (30) (Fig. 4E).  A previous study suggested that 
OCT2 expression is itself controlled by IL10-JAK-STAT3 signaling (31). We confirmed 
this regulation by analysis of mRNA from HBL1 ABC DLBCL cells treated with JAK 
kinase inhibitors (ruxolitinib, AZD1480) or stimulated with IL10 (Fig. S5D), suggesting 
the existence of positive feedback loop.   Other than OCT2 itself, no single gene ( 
STAT3, MYC, MYB, ADA & BCL6) could reverse the toxicity of OCT2 depletion in 
DLBCL lines when expressed ectopically (Fig. S5E), consistent with the concept that 
OCT2 regulates a network of many genes rather than a single dominant downstream 
target. 
The genes and signatures most negatively correlated with OCT2 and OCA-B were 
enriched for those reflecting the action of type I interferon.  Indeed, knockdown of OCT2 
led to enhanced transcription from an Interferon Response Element luciferase reporter  
(Fig. S5F). Furthermore, overexpression of OCT2 substantially reversed the expression 
of genes from the IFN-3 gene expression signature, which includes genes that are induced 
by interferon (Fig. S5G, H). Thus it is conceivable that the toxicity of OCT2 depletion 
may be mediated in part by the induction of a type I interferon response, which is 
deleterious to DLBCL cells (32). 
To identify genes regulated by OCT2 in normal mouse B cells, we profiled gene 
expression in purified splenic B cells from wild type or Pou2f2fl/fl mice, in which Pou2f2 
deletion was induced ex vivo by tamoxifen.  Cells were analyzed after 48 hours of 
tamoxifen treatment, at which time almost complete depletion of OCT2 protein was 
observed by immunoblot.  Analysis of genes with lower expression in the knockout B 
cells revealed enrichment of multiple GO ontology terms related to toll-like receptor 
signaling, B cell proliferation and B cell activation (Table S1).  Individual genes of 
particular interest included Lmo2, Cd22, Il10, Bach2, Spib and Stat3, which were either 
identified as OCT2 targets in DLBCL cells or were previously suggested to be OCT2 
targets.  We used qRT-PCR to validate Stat3, ADA, Ell2 (each of which were also OCT2 
targets in DLBCL) as OCT2 targets in sorted germinal center B cells from immunized 
mice. (Fig. 4F). Taken together, these studies demonstrate that OCT2 controls a broad 
program of genes and pathways critical to normal B cell function in both malignant 
human B cells and normal mouse B cells. 
 
Recurrent genetic aberrations targeting OCT2 in DLBCL.  Analysis of previously 
published array comparative genomic hybridization (aCGH) data from DLBCL identified 
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5 samples with amplifications encompassing the POU2F2 locus, each of which had 
increased OCT2 mRNA levels (Fig. 5A) (33).  In three cases, the amplicon was less than 
1 megabase in size, and in the GCB DLBCL line BJAB, the amplicon only included one 
other gene, ZNF574, of unknown function, suggesting that these amplifications were 
selected to increase OCT2 expression.  An additional 6 cases had amplifications of the 
POU2AF1 locus, encoding OCA-B, with overexpression of OCA-B mRNA (Fig. 5A).  
The minimal common amplified region included only 6 other genes, none of which are 
expressed in B cells, suggesting that OCA-B was the focus of these genetic events.  
These recurrent amplifications of the genes encoding OCT2 and OCA-B suggest an 
oncogenic role for these factors in DLBCL. 
Based on a report of OCT2 POU domain mutations in follicular lymphoma (24), 
we sequenced the exons encoding the POU domain in 207 cases of DLBCL.  Twelve 
non-synonymous, heterozygous mutations were observed, with a mutational hot spot 
targeting threonine 223 (T223) in 7 cases, substituting either alanine or serine (Table S2). 
T223 is located in the POU-specific domain and inserts into the DNA major groove, 
making contact with G3 of the octamer motif (Fig. 5B).  Compared to wild type OCT2, 
ectopic expression of OCT2 T223A was much less effective in rescuing DLBCL cells 
from the toxicity of OCT2 knockdown (Fig. 5B and Fig. S6A).  To test whether the 
T223A mutant isoform alters OCT2 DNA binding, we designed "Biotag" constructs that 
express either wild type or T223A OCT2 fused to a peptide sequence that can be 
biotinylated by the bacterial enzyme BirA.  We engineered the DLBCL cell line BJAB to 
express BirA, transduced the cells with the OCT2 Biotag constructs, and performed 
ChIP-seq using streptavidin to purify chromatin bound to these OCT2 isoforms (Fig 
S6B).  The majority of regions bound by wild type OCT2 were also bound by OCT2 
T223A, indicating that T223A is not a complete loss-of-function mutant (Fig. 5D, 5G).  
Roughly 10% of the T223A binding peaks (n=2975) had reduced or no binding by wild 
type OCT2.  MEME analysis of these peaks revealed strong enrichment for an altered 
octamer motif 5’-ATACAAAT-3’, which has an A in the position of the motif that is 
contacted by T223 (Fig. 5E, F, H). To identify genes regulated by OCT2 T223A, we 
profiled gene expression in lymphoma lines in which we ectopically expressed either 
wild type or T223A OCT2 following knockdown of endogenous OCT2 expression. 
While OCT2 T223A-expressing cells had reduced expression of previously identified 
OCT2 target genes and signatures (Table S3), the expression levels of a number of genes 
and signatures were increased by this mutant.  This gene set was enriched for genes with 
OCT2 T223A binding peaks, such as FCRL2, FCRL3 and HIF1A (Table S3).  
Accordingly, signatures of HIF1α-dependent target genes were enriched in HBL1 cells 
expressing T223A (Table S3), and increased cell surface expression of FCRL2 and 
FCRL3 was confirmed by flow cytometry  (Fig. S6C). 
Four of the DLBCL biopsies with OCT2 T223 were included in a previous RNA-
Seq study (30), allowing us to search for genes that were expressed differentially in these 
cases versus others with wild type OCT2.  Integrative analysis revealed 10 genes that 
were more highly expressed in OCT2 T223A+ biopsies and were also bound 
preferentially and upregulated by OCT2 T223A in vitro.  Among these was HIF1A, and 
accordingly, multiple signatures of HIF1α target genes were enriched in OCT2 T223A+ 
cases (Table S3).  Also included was FCRL3, which was bound and regulated by OCT2 
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T223A in our cell line models. Taken together, these findings suggest that OCT2 T223 is 
an altered function mutant that subtly shifts the repertoire of OCT2 regulated genes. 
 
The OCT2/OCA-B interface as a potential target for therapeutic development.  
Given the essentiality of both OCT2 and OCA-B in DLBCL lines, we investigated 
whether the interface between these two proteins might be a potential therapeutic target. 
The POU domain of OCT2 is highly homologous to that of OCT1, allowing us to use the 
crystal structure of the ternary complex between OCT1, OCA-B and the octamer motif 
along with mutational studies of OCT1 to predict which amino acids of OCT2 are critical 
for its interaction with OCA-B (5, 6).  We created OCT2 and OCA-B mutant isoforms 
that were predicted to disrupt the association of these proteins by introducing single 
alanine substitutions of residues in the OCT2 POU-specific domain (L184, E185; 
accession NP_001234923) and the POU homeodomain (K335, I339), as well as a proline 
substitution of L32 of OCA-B (Fig. 6A).  Whilst the toxicity of OCT2 or OCA-B 
knockdown in the ABC DLBCL line OCI-Ly10 was reversed by ectopic expression of 
the respective wild type isoforms, the mutant OCT2 and OCA-B isoforms had little if any 
activity (Fig. 6B,C & Fig. S6D-G). Thus, the residues that facilitate the interaction of 
OCT2 and OCA-B are essential for the survival of DLBCL cells. 
 
Discussion 
Our genetic and functional analyses have clarified the role of OCT2 in normal and 
malignant B cells.  Previous studies of Rag2-deficient mice reconstituted with OCT2 
knockout bone marrow have yielded conflicting evidence regarding the role of OCT2 in 
the germinal center reaction (14, 15).  By conditional deletion of Pou2f2, we observed 
normal formation of germinal centers in the absence of OCT2, yet the cell cycle 
progression of the B cells in these germinal centers was impaired.  While the 
development of memory B cells proceeded normally following immunization of OCT2-
deficient mice, these mice were strikingly unable to form antibody-secreting plasma cells. 
Hence, our genetic analysis revealed that OCT2 influences the dynamic behavior 
germinal center B cells in vivo by promoting their proliferation and plasmacytic 
differentiation. 
In contrast to the rather selective germinal center defects resulting from OCT2 
deficiency, we observed that all human DLBCL lines tested are strongly addicted to the 
expression of OCT2.  DLBCL tumors arises from normal B cells that have traversed the 
germinal center, and either retain the germinal center phenotype, in the case of the GCB 
subtype, or undergo partial plasmacytic differentiation, in the case of the ABC subtype.  
The fact that OCT2-deficient germinal center B cells have a defect in proliferation may 
contribute to the toxicity of OCT2 knockdown in DLBCL lines.  However, depletion of 
OCT2 in DLBCL not only blocks proliferation, but also induces cell death, suggesting 
that OCT2 functions in a somewhat different or augmented fashion in malignant versus 
normal B cells.  A role for OCA-B in DLBCL was previously revealed by the discovery 
of a DLBCL-specific super-enhancer in the POU2AF1 locus (23), but this study did not 
address whether OCA-B mediates its effects in DLBCL through OCT1 or OCT2.  We 
cannot exclude a contribution from OCT1, however, our data suggest that OCT2 is the 
key factor cooperating with OCA-B, a view that is supported by our genetic analysis of 
DLBCL tumors, which revealed recurrent amplification of POU2F2 locus.  Likewise, we 
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observed recurrent amplification of the POU2AF1 locus in DLBCL tumors, but not the 
POU2F1 locus, which encodes OCT1. However, amplification of POU2F2 and 
POU2AF1 were detected in only ~3% (5/172) of DLBCL tumors tested, which by itself 
might have led to the conclusion that OCT2 and OCA-B contribute only infrequently to 
DLBCL pathogenesis.  Given the universal addiction of DLBCL lines to OCT2 and 
OCA-B, our study highlights the power of functional genomic methodologies to uncover 
essential cancer mechanisms. 
By combining ChIP-seq with gene expression profiling, we identified multiple 
OCT2 target genes that play important roles in B cell function and differentiation, 
including ELL2, XBP1, MYC, TERT, ADA, IL10 and STAT3.  Gene expression signature 
analysis revealed that many of the OCT2 target genes are involved in key regulatory 
pathways in DLBCL (MYD88, NF-κB, STAT3 and IRF4).  Although OCT2 did not 
directly regulate IRF4 or PRDM1, the direct regulation of STAT3 and its activation by 
autocrine production of IL-10 were particularly intriguing given the known role of 
STAT3 in the transactivation of PRDM1 and the initiation of plasma cell differentiation. 
STAT3 appears to play a particularly important role in the differentiation of germinal 
center B cells to plasma cells (34), an effect that may depend upon synergism with CD40 
signaling (35).  There are similarities between the phenotypes of OCT2 conditional 
knockout mice and IL-21 receptor knockout mice, in which germinal centers and memory 
B cells are formed but germinal center proliferation and plasma cell differentiation are 
reduced (36), which is intriguing given that IL-21 receptor signaling activates STAT3.  
The OCT2 target ELL2 is required for the alternative splicing needed to produce soluble 
immunoglobulin and regulates the unfolded protein response during plasma cell 
differentiation, together with XBP1, also an OCT2 target. Ell2 knockouts show decreased 
plasma cell numbers as well as also reduced expression of OCA-B suggesting a feed 
forward loop during plasma cell differentiation (37).  The OCT2 target gene ADA 
encodes adenosine deaminase, which prevents apoptosis during B cell activation and is 
required for the formation of germinal centers (38).  Thus, the identified OCT2 
transcriptional program is consistent with the growth and survival of normal and 
malignant germinal center B cells and also with the control of post-germinal center 
plasma cell differentiation by OCT2. 
The recurrent POU2F2 T223A mutation targets a residue in the POU-specific 
domain that directly contacts the octamer motif within the DNA major groove.  A 
previous analysis posited that this mutation was loss-of-function (24), but this conflicts 
with other evidence that OCT2 performs an oncogenic function in DLBCL and with the 
fact that DLBCL tumors do not acquire nonsense or frame shift mutations in POU2F2, 
nor do they delete this gene frequently.  Instead, our ChIP-Seq and gene expression data 
suggest that the OCT2 T223A is a neomorphic mutation that is associated with some 
reduction in transcriptional programs regulated by wild type OCT2 (Table S3), but also a 
gain in expression of non-canonical target genes that have an altered octamer motif in 
which the base contacted by T223 is changed from guanine to adenine.  In DLBCL 
tumors, the T223A mutation is invariably heterozygous, suggesting a role for the 
remaining wild type OCT2 allele.  This observation may explain why cells engineered to 
only express OCT2 T223A were not as fit as those with wild type OCT2.  Alternatively, 
DLBCL tumors with OCT2 T223A may acquire additional genetic or epigenetic changes 
that permit them to tolerate its altered regulatory repertoire.  In this regard, an intriguing 
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hypothesis is that the OCT2 T223A isoform may promote lymphomagenesis by blocking 
plasmacytic differentiation, which OCT2 normally promotes.  Indeed, genetic events that 
block full plasmacytic differentiation are recurrent in ABC DLBCL, including multiple 
lesions that inactivate Blimp1 (reviewed in ref. (39)).  Hence, DLBCL tumors may 
acquire T223A and lose one wild type OCT2 allele in order to partially block plasmacytic 
differentiation.  In addition, one of the non-canonical targets of OCT2 T223A is FCRL3, 
which encodes a transmembrane protein with both ITAM and ITIM domains that 
enhances TLR9-mediated B cell proliferation and survival while at the same time 
inhibiting plasma cell differentiation (40).  Future analysis of T223A knock-in mice 
would be helpful in testing the hypothesis that OCT2 T223A blocks post-germinal center 
plasmacytic differentiation. 
The present study identifies OCT2 as an attractive therapeutic target in DLBCL. 
Knockdown of OCT2 was toxic to models of both ABC and GCB DLBCL, suggesting 
that agents targeting OCT2 would transcend the many regulatory differences between 
these subtypes (39).  Recent clinical trials have focused on oncogenic pathways in ABC 
DLBCL (41) but methods to target GCB DLBCL are also needed.  The B cell-restricted 
expression of OCT2 and OCA-B suggest that inhibition of these proteins in human 
patients would not be associated with generalized toxicity.  Consistent with this, the 
induced deletion of OCT2 in adult mice was associated with no outward signs of ill 
health.  Finally, our work suggests that agents targeting the OCT2/OCA-B interface 
might be one possible strategy. Alternatively, new methods to target proteins for 
destruction using small molecules (42, 43) might be aimed at OCT2 for the therapy of 
DLBCL. 
 
Materials and Methods 
Pou2f2 targeted JM8A3.N1 embryonic stem cells were purchased from the EUCOMM 
Consortium; clone ID HEPD0690_4_H11, IKMC Project 82506, allele name 
Pou2f2_tm1a(EUCOMM) Hmgu, MGI allele ID MGI:101897.  All animal experiments 
were carried out in accordance with the National Cancer Institute Animal Care and Use 
Committee guidelines and approval.  A detailed description of all methods is available in 
the SI Materials and Methods. 
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Fig. 1.  Defective germinal center function in pou2f2 knockout mice.  (A) FACS plots 
gated on B220+ splenic B cells showing germinal center B cells in mice seven days after 
immunization with sheep red blood cells.  (B) Germinal center B cell turnover measured 
by pulsed EDU incorporation in mice 14 days after IP with NP-KLH. (C) NP specific 
serum IgG1 and IgM immunoglobulin responses at day 14 and day 28 after 
immunoprecipitation with NP-KLH. Total and high affinity immunoglobulin measured 
with NP30 and NP4 conjugated BSA is indicated along with the measured isotype. (D) 
Antigen specific antibody secreting cells (ASC) quantified by ELISpot on spleen or bone 
marrow (BM) 28 days after immunization with NP30 (total) or NP4 (high affinity) 
conjugated bovine serum albumin. (E) Representative FACS plots of NP-specific 
memory B cells from mice seven days after secondary immunization. FACS plots shown 
are gated on B220+, Dump-(Gr1-CD11d-IgM-IgD-CD138-).  Cells with a memory B cell 
(MBC) phenotype (B220+, Dump-,CD38+) are enumerated as cells per million 
lymphocytes. 
 
Fig. 2.  DLBCL Cell lines are addicted to expression of OCT2. Viability of DLBCL 
lines transduced with shRNAs targeting OCT2 (shOCT2 #1) (A) or OCA-B (B).  Shown 
are the percentages of live shRNA expressing cells over time relative to the day 0 value. 
Error bars represent SEM of replicate experiments, with the number of replicates shown 
in parenthesis. 
 
Fig. 3. OCT2 and OCA-B bind an overlapping repertoire of genomic loci (A) 
Classification of OCT2 and OCA-B binding peaks as promoter (TSS +/- 2kb), upstream 
(TSS -15Kb to -2KB), gene body or intergenic regions.  (B) Overlap of genes with an 
OCT2 or OCA-B peak within a gene window (TSS – 15Kb through gene body).  (C) 
Proportion of OCT2 binding peaks that overlap with OCA-B peaks as a function of 
OCT2 peak size (left).  Proportion of OCA-B peaks overlapping with an OCT2 peak as a 
function of OCA-B peak size (right).  Total number of peaks (black line) is overlaid (D) 
Motif discovery using MEME.  The most enriched motifs are shown based upon the top 
1,00 peaks from each class of peak as indicated. (E) Percentage of OCT2 or OCA-B 
peaks that contain the octamer motif (ATGCA[A/T]AT) as a function of peak size.  (F) 
Examples of OCT2 binding peaks (blue peaks) with large (left), small (middle) or no 
(right) overlapping OCA-B peaks (red peaks), with the best octamer sequence indicated.  
Y-axis shows ChIP-Seq read counts. 
 
Fig. 4. OCT2 and OCA-B regulate a broad program of B cell gene expression. (A) 
Direct OCT2 target genes identified from both ChIP-Seq and reduced expression 
following OCT2 knockdown. Genes are grouped by overlap with functionally related 
gene expression signatures.  Red indicates genes with OCT2 and OCA-B overlapping 
ChIP-Seq peaks within the gene window.  Black indicates OCT2 isolated peak within 
gene window. Bold print indicates peak is within 2KB of TSS.  (B) IL10 mRNA 
expression quantified by qRT-PCR following OCT2 shRNA knockdown relative to B2M 
in HBL1 cells.  (C) IL10 measured by ELISA in cell supernatants following OCT2 
shRNA knockdown in HBL1 and Ly10 cells. (D) Expression of total STAT3 following 
14
OCT2 shRNA knockdown in TMD8.  (E) Correlation of POU2F2 and STAT3 mRNA 
expression by digital gene expression in GCB (top) and ABC (lower) DLBCL biopsy 
specimens. (F) Confirmation of selected mRNA expression changes by qRT-PCR 
analysis of RNA from sorted germinal center B cells from mice seven days after 
intraperitoneal immunization with sheep red blood cells. 
 
Fig. 5.  Recurrent genetic alteration of POU2F2 in DLBCL. (A) Amplification of the 
POU2F2 and POU2AF1 loci in DLBCL biopsies and cell lines analyzed by aCGH.  Red 
lines indicate amplified regions.  (B) Crystal structure of the OCT1 POU domain 
interacting with the octamer sequence and OCA-B.  Yellow helices represent POU 
specific domain, red helix is POU homeodomain and purple helix is OCA-B.  The 
elemental structure of T223 and the guanine at position three of the octamer motif is 
shown. (C) OCT2 WT but not OCT2 T223A is able to rescue Ly10 cells depleted of 
OCT2 by shRNA. (D) Overlap between genes with an OCT2 WT or T223A BioChIP 
peaks in a gene window (TSS – 15Kb through gene body).  (E) Motif discovery using 
Weeder based on the top 1,000 OCT2 BioChIP peaks.  OCT2 WT (top) OCT2 T223A 
(lower panel). (F) Motif discovery using MEME based on top 1,000 OCT2 BioChIP 
peaks.  OCT2 WT (top) OCT2 T223A (lower panel). (G) Examples of genes with similar 
binding between WT and mutant OCT2. Best octamer motif are shown. (H) Examples of 
genes with preferential binding by OCT2 T223A.  The best octamer motif identified 
within 200nt peak window is indicated. 
 
Fig. 6. The OCT2-OCA-B interface as a potential target for drug therapy. (A) 
Crystal structure showing the OCT1 POU domain (yellow) in complex with OCA-B 
(purple) and the octamer motif.  Residues mutated to abolish the OCT2/OCA-B 
interaction are shown in white.  (B) Rescue experiment in Ly10 cells transduced with an 
OCT2 shRNA and either wild type (WT) or POU domain mutant OCT2 constructs, as 
indicated. (C) Rescue experiment in Ly10 cells transduced with OCA-B shRNA and 

















































































































































































































Fig. 1.  Defective germinal center function in Pou2f2 knockout mice.  
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Online methods  
 
Animals 
All animal experiments were carried out in accordance with the National Cancer Institute 
Animal Care and Use Committee guidelines and approval.  Pou2f2 targeted JM8A3.N1 
embryonic stem cells were purchased from the EUCOMM Consortium; clone ID 
HEPD0690_4_H11, IKMC Project 82506, allele name Pou2f2_tm1a(EUCOMM)Hmgu, MGI 
allele ID MGI:101897.   Correct targeting was verified by Southern blotting and ES cells 
were injected into C57Bl6.  Chimeras were bred to albino C57Bl6 females and F1 mice were 
genotyped by Southern Blot.  Heterozygous F1 mice were crossed to FLPE(25) expressing 
mice from Jackson (B6.Cg-Tg(ACTFLPe)9205Dym/J)  and then to ROSA26-Cre-ER mice 
(NCI Mouse Repository) (26).  Pou2f2 genotype was determined by PCR using the following 
primers forward: 5’-GGTCACAAAGGGACACGGTTTC-3’ and reverse: 5’-
GATGGTTTGGTAGACGAAGTCACTCC-3’.  Cre expression was induced by 
intraperitoneal injection of tamoxifen (Sigma) given as five doses with a minimum seven day 
interval before immunization or analysis as previously described(44). 
 
Southern blotting  
Genomic DNA was digested overnight with the indicated restriction enzymes, run on an 
agarose gel and transferred to Hybond-XL membrane as per manufacturers protocol. Neo 
probes and flanking probes were labelled using the Rediprime labelling kit and hybrisized 
using Rapid-Hyb buffer (both from GE) and used as per the manufacturer’s protocols.  Probes 
were cloned using the flowing primers:  
Neo-F; 5’-AACAAGATGGATTGCACGC-3’,  
Neo-R;5’-CGGGTAGCCAACGCTATGTC-3’,  




For primary immunisation mice (8-12 weeks old) received intraperitoneal injection of 100ug 
of NP(19)-KLH (Biosearch Technologies) adsorbed to Alum (Thermo Scientific).  For 
secondary immunisation soluble NP(19)-KLH alone was used. Blood was collected by tail 
bleed or terminal cardiac puncture at the indicated time points.  For germinal center induction 
mice were immunised with 100ul of 10% sheep red blood cells (Colorado Serum Company). 
 
Measurement of NP-specific immunoglobulin and antibody secreting cells 
Maxisorb (Nunc) ELISA plates were coated with 1µg/ml NP(27)BSA or NP(4)BSA in 
carbonate buffer before blocking in 1% BSA.  Dilutions of serum were added. Captured 
immunoglobulin was detected using anti-IgM or IgG1 conjugated to HRP (Southern 
Biotechnology Associates).  SigmaFast OPD substrate reagent (Sigma) was added and the 
reaction quantified using a Spectromax 250 96- well plate reader.  Values in the linear range 
were used to calculate relative titre using the endpoint dilution method(45).  For ELISpot 
Multiscreen HA mixed cellulose ester plates (Millipore) were coated with NP-BSA in PBS 
before blocking in 1% BSA and incubation overnight with a known concentration of cells.  
Plates were then washed with PBS/Tween and incubated with anti-IgM or IgG1 conjugated to 
HRP (Southern Biotechnology Associates).  Spots were then visualized using the AEC 




Mouse cell FACS and sorting 
Flow cytometry analysis was performed on an LSRII (BD).  FlowJo software (TreeStar) was 
used for data analysis. Cell suspensions of murine splenocytes were prepared in PBS with 2% 
FCS.  Red cells were removed using Red Cell Lysis Buffer (Biolegend) then pre-incubated 
with purified anti-CD16/CD32 FC blocking antibody (eBioscience) prior to immunostaining 
with the following antibodies or markers: B220, CXCR4, CD83, CD86 (eBiosciences), 
CD95, CD11b, Gr1, IgD, CD138 (BD), IgG1, CD38 (Biolegend), PNA (Sigma), NP-BSA-
Biotin (Biosearch). The EdU staining kit (Life Technologies) was used as per the 
manufacturer’s protocol. Mice received one intraperitoneal injection of EDU 5 hours prior to 
harvesting splenocytes for FACS analysis of germinal center B cells. FACS sorting was 
performed on a FACSAria cell sorter. Prior to sorting of mouse germinal center B cells, 
splenocytes were pre-enriched my magnetic selection as previously described(46).  
Intracellular staining of lymphoma cell lines was performed after fixation with 
Cytofix/Cytoperm using Caspase3 and cleaved PARP antibodies from BD biosciences.  Cell 
cycle analysis was performed after staining with DAPI (Sigma). 
 
In vitro stimulation murine B cells 
B lymphocytes were purified from spleens of non-deleted mice by magnetic bead technology 
(B cell isolation kit, mouse, Miltenyi Biotech).  Cells were stimulated in vitro with 5ug/ml 
anti-IgM (Jackson), 10ng/m lIL4 (Promega) in the presence of 5-OH-tamoxifen (Sigma).  At 
48 hours OCT2 was efficiently depleted and 50ng/ml IL21 (Promega) was added.  Cells were 
harvested 12 hours later. 
 
RNA extraction and qPCR 
Cells were lysed in Trizol and RNA purified using RNeasy columns (Qiagen). CDNA was 
made using Superscript III (Life technologies).  Taqman assays were run an ABI7500 
instrument (Applied Biosystems) using the following assays hB2M (Hs00984230_m1), hIL10 
(Hs00961622_m1), mPou2f2 (Mm01149405_m1), mStat3 (Mm01219775_M1), mAda 
(Mm00545720_m1), mEll2 (Mm00507237_m1). 
 
Lymphoma cell line culture and retroviral production 
OCI cell lines were cultured in Iscove’s medium with 20% fresh human plasma.  All other 
cell lines were cultured in RPMI, penicillin/streptomycin and 10% fetal bovine serum. Cells 
were maintained in a humidified, 5% CO2 incubator at 37°C. All cell lines were engineered 
to express an ecotropic retroviral receptor and the bacterial tetracycline repressor as 
previously described(47). Production of retroviruses was performed by co-transduction of 
293T cells, with Transit293 (Mirus) with plasmids containing gag & pol genes, the ecotropic 
envelope protein, and the retroviral construct. 
 
Plasmids 
OCT2 was cloned from cDNA from BJAB and OCA-B cDNA was purchased from Origene.  
Both were cloned into the vectors pCMV-TOP and pFlagBiopCMV-TOP(30).  Site directed 
mutations were introduced using the QuikChange Lightning kit from Agilent. shRNAs 
targeting OCT2 or OCA-B were designed and cloned as double stranded oligonucleotides into 
a retroviral vector (pRSMX_PuroGFP) for doxycycline-inducible shRNA expression, as 
previously described(47).  RNAi sequences used are as follows:   
OCT2 shRNA#1_1196 5’-GCACAACAGTTACTACCTTAT-3’,  
OCT2 shRNA#2_3410 5’-GGATGCTTCTTTCTCTTCACA-3’,  
OCA-B shRNA_3017 5’-CAGCCAGAAGTACCATTAGG-3’.    
Because OCT2 shRNA#1 targeted the coding region of OCT2 silent mutations were 




The pRSMX-PG vector coexpressing GFP and shRNA was introduced into cells and where 
required selection was carried out with puromycin.  Expression of shRNA was induced by 
addition of doxycycline (50 ng/mL). For toxicity screen, the fraction of GFP+, shRNA-
expressing cells was quantified by flow cytometry using a BD FACS Calibur at the indicated 
time points and normalized to the day 0 fraction of GFP+ cells.  
 
Western blotting 
Cell pellets were lysed in RIPA buffer with a protease inhibitor cocktail (Roche), separated 
on 4-12% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. Antibodies 
used were OCT2 (SC-233), OCA-B  (SC-955) and Actin-HRP (Santa Cruz) and STAT3 
(CST). 
 
IL10 ELISA and IFN reporter assay  
IL-10 was quantified using the IL-10 Quantikine colorimetric sandwich enzyme-linked 
immunosorbent assay kit (R&D Systems) according to the manufacturer’s instructions. IFN 
reporter experiments were conducted using a previously described reporter cell line(32) 
 
Chromatin immunoprecipitation and ChIP-Seq 
ChIP and ChIP-Seq was performed as previously described(48) using antibodies OCT2 (SC-
233), OCA-B  (SC-955) and anti-Flag M2 (Sigma) and sequenced on GAIIX genome 
sequencer.  Motif discovery was performed using MEME or Weeder based on a 200nt 
window centred on the peak apex (49, 50).  The following qChIP primers were used: 
STAT3 promoter F:  5’-CCACTGACCAATGAGGAGAGCAG-3’,   
STAT3 promoter R: 5’-AGGGAGGAGCACCGAACTGTC-3’ 
Negative control F:  5’-ACAGGCTTCAAGGGACATCTCTC-3’  
Negative control R: 5’- TGCTCACGGTTTGTTTGTTTCC-3’. 
 
BioChIP  
N-terminally tagged OCT2 in the vector pRCMV/TOP_Flag-Bio or empty vector was used to 
transduce cells engineered to express the BirA enzyme.  Selection was carried out using 




Gene expression profiling by microarray 
Total RNA was extracted with TRIzol (Invitrogen) and subsequently cleaned up with RNeasy 
mini columns (Qiagen). Gene expression profiling was performed using two-color human 
Agilent 4×44K or mouse 8x60K gene expression arrays, as described by the manufacturer, 
comparing signal from control cells (Cy3) and experimentally manipulated cells (Cy5). Array 
elements were filtered for those meeting confidence thresholds for spot size, architecture, and 
level above local background. These criteria are a feature of the Agilent gene expression 
software package. Gene set enrichment was performed as previously described (30). GO term 




Supplementary Figure Legends 
 
Fig. S1.  Generation and validation of a conditional pou2f2 knockout mouse. (A) 
Map of the targeted pou2f2 locus prior to FLP recombinase mediated removal of the 
FRT flanked neo cassette.  Positions of the 5’ and 3’ homology arms are shown along 
with exons (yellow), FTR and LoxP positions. (B) Map of the targeted Pou2f2 locus 
after removal of the FRT flanked neo cassette.  Positions of the 5’ probe and 
Neomycin probe used in Southern blots are shown along with restriction sites. 
N=NCO1, B=BSTEII, P=PME1, E=ECOR1, A=AVRII.  (C) Southern blotting of 
genomic DNA purified from F1 mouse tail digested with the indicated enzymes and 
using the 5’ probe. Expected band sizes are shown. (D) Southern blotting of genomic 
DNA purified from F1 mouse tail digested with the indicated enzymes and using the 
Neomycin probe. Expected band sizes are shown.  (E) qRT-PCR for Pou2f2 using a 
PCR assay spanning exons 10-11 of pou2f2 in cDNA from germinal center B cells 
sorted from mice of the indicated Pou2f2 genotype.  (F) Western blot for OCT2 in 
splenic B cells from mice of the indicated Pou2f2 genotype.  (G) RNA seq from 
sorted germinal center B cells showing persistence of a Pou2f2 transcript lacking 
exons 8-11 in homozygous pou2f2 knockout mice.    
 
Fig. S2. Defective germinal center function in Pou2f2 knockout mice.  (A) 
Germinal center (GC) B cells in Pou2f2 knockout mice following immunization with 
sheep red blood cells. FACS plots gated on B220 positive lymphocytes show 
germinal center (GC), light zone (LZ) and dark zone (DZ) distribution. (B) 
Quantification of germinal center B cells in five heterozygous and eight homozygous 
Pou2f2 knockout mice. (C) Gating strategy used for assessment of EDU incorporation 
to assess germinal center turnover. (D) Representative ELISpot wells 28 days after 
immunization with NP30 (total) or NP4 (high affinity) conjugated BSA. (E) Gating 
strategy and quantification of switched antigen-specific B cells 28 days after primary 
immunization with NP-KLH.  (F) Representative FACS plots NP-specific memory B 
cells from mice seven days after secondary immunization including controls 
immunized at only a single timepoint. . FACS plots shown are gated on B220+, Dump-
(Gr1-CD11d-IgM-IgD-CD138-).  (G) Quantification of the humoral response to 
secondary immunization in mice seven days after secondary immunization with NP-
KLH. 
 
Fig. S3. DLBCL cell lines are addicted to both OCT2 and OCA-B. (A) Depletion 
of an OCT2 shRNA in a loss of function RNA interference screen using a panel of 
lymphoid cell lines 21 days after shRNA induction.  (B) Viability of cells transduced 
with a second shRNA targeting OCT2 (sh-OCT2 #2).  Shown is the percentage of live 
shRNA expressing cells over time relative to the day 0. Number of replicate 
infections is shown in parenthesis. Error bars represent the SEM of replicates.   (C) 
Rescue of each OCT2 shRNA by overexpression of OCT2 cDNA or empty vector in 
Ly10 cell line.  Error bars for Oct2 shRNAs show SEM of 3 replicates.  (D) 
Representative cell cycle analysis plots in BJAB 4 days after induction of the 
indicated shRNAs. Bar chart shows summary of 3 experiments in BJAB and 2 
experiments in HBL1.  (E) Representative FACS plot showing intracellular staining 
for active Caspase3 and cleaved PARP in BJAB 4 days after induction of the 
indicated shRNAs. Bar chart shows summary of 3 experiments in BJAB and 2 
experiments in HBL1.  (F) Rescue of OCA-B shRNA by overexpression of the OCA-
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B cDNA or empty vector in Ly10 cell line.  (E) Immunoblots of OCT2 and OCA-B in 
BJAB and HBL1 cell lines transduced with shRNAs to OCT2 or OCA-B at day 1 and 
day 2 following shRNA induction. 
 
Fig. S4.  OCT2_Common_UP gene expression signature in all cell lines tested.  
Two shRNA (OCT2#1 and OCT2#2) were transduced, selected and induced in five 
DLBCL cell lines. RNA was harvested for each at 24 and 48 hours post induction to 
give 4 data points per cell line. Significantly changing genes were those with log2 
fold change >0.4 up or down in three or more data points.  Genes with decreased 
expression in two or more cell lines were used to generate the OCT2_Common_UP 
signature.  Also shown is the OCT2_Common_UP signature genes in a replicate 
HBL1 and Ly10 experiment and an OCA-B shRNA knockdown experiment. 
 
Fig. S.5. OCT2 promotes STAT3 expression and represses IFN activity.  (A) 
STAT3_UP2 signature genes after knockdown of OCT2  (B) Dauer_STAT3_Down 
signature genes after knockdown of OCT2 (C) ChIP-qPCR for OCT2 or isotype 
control at the STAT3 promoter. (D) HBL1 cells were treated with the JAK inhibitors 
Ruxolitinib or AZD1480 or stimulated with IL10 (50ng/ml) for the indicated times 
(hours) then POU2F2 mRNA expression quantified by qPCR. (E) Rescue experiments 
in cell lines transduced with empty control vector, OCT2 or the indicated cDNA 
followed by OCT2 shRNA. (F) An Ly10 Interferon Response Element (IRSE) 
luciferase reporter cell line was transduced with either control or OCT2 shRNA.  
Luciferase activity was measured before and eight hours after addition of IFN-beta 
(48 hours after shRNA induction). (G) Expression of upregulated genes from an 
interferon signature (IFN3) in HBL1 cells depleted of OCT2 by shRNA and rescued 
with either control empty vector or OCT2 WT. (H)Western blot showing expression 
of endogenous and tagged, transduced OCT2 in HBL1 cells used for rescue 
experiment in (G).   
 
Fig. S6.  Altered function mutations of OCT2.  (A) Rescue experiments in HBL1 
ad BJAB cell lines using OCT2 WT, OCT2 T223A or empty vector to rescue OCT2 
shRNA#1. (B) expression of endogenous and tagged, transduced OCT2 constructs 
used in rescue and BioChIP experiments in BJAB. A flag-bio tag allows the 
transduced protein to be visualized above the endogenous protein. (C) Expression of 
FCRL2 and FCRL3 by flow cytometry in BJAB and HBL1 cells transduced with 
either OCT2 WT or OCT2 T223A. Shown are SEM or 2 (WT) or 3 (mutant) 
independently generated cell lines.  (D) Rescue experiments in HBL1, BJAB and 
SUDHL4 cell lines transduced with shRNA to OCT2 and either wild type (WT) or 
mutant OCT2 rescue construct as indicated. HDM = homeodomain K335A / I339A 
double mutant.  PSM = POU specific domain L184A / E185A double mutant.  Where 
shown error bars are SEM of 3 experiments.  (E) Rescue experiment in HBL1, BJAB 
and SUDHL4 cell lines transduced with OCA-B shRNA and either WT or mutant 
(L32P) OCA-B rescue construct.  (C & D) Western blot showing relative expression 




Table S.1.  B cell signatures and GO terms associated with OCT2. Shown are B cell 
signatures enriched in three or more of five cell lines after shRNA knockdown of 
OCT2 or OCA-B. Input gene sets (OCT2Up or OCA-BUp) consist of genes with 
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decreased expression following OCT2 / OCA-B knockdown (up>0.4 or down <-0.4 
(log2) in at least three out of four timepoints).  Shown is data from the cell line in 
which the signature was most enriched.  Signature enrichment thresholds: Intersection 
>=10, Enrichment >2, Confidence interval >1.5.  Input genes are those. GO terms 
associated with genes with decreased expression in Pou2f2 knockout murine splenic 
B cells stimulated in vitro ranked by fold enrichment. 
 
Table S.2.  Results of Sanger Sequencing of the POU2F2 POU domain in 207 
DLBCL biopsies and cell lines.  
 
Table S.3.  Enrichment analysis of Broad Institute molecular signatures amongst 
genes differentially expressed in cell lines in which endogenous OCT2 was knocked 
down and rescued by T223A vs WT OCT2 (Table 4A) or genes with enhanced or 
reduced expression (measured by RNA-seq) in human DLBCL biopsies from tumors 
with T223A mutated OCT2 compared to cases with wild type OCT2 (Table 4B).  
Enrichment analysis of B cell signatures (including OCT2 signatures) amongst genes 
with altered expression in cell lines in which OCT2 was knocked down and rescued 
























NCOI BSTEII ECORIBSTEII AVRII PMEI
5” flanking probe Neomycin probe
A
D
Enzyme WT Targeted 
NCOI 7.1kb 8.1kb 
BSTEII 6.8kb 13.9kb 
Enzyme WT Targeted 
BSTEII No band 13.9kb 
ECORI No band 13.9kb 
AVRII No band 10.5kb 
PMEI No band 11.9kb 
C
B
5’ Homology 3’ Homology 
5’ flanking probe Neomycin probe 
B E P A N A E P 
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 RASSF6  AEN  MAP3K6  SIRT3  MMP11  LRRC16B  PRR7  HOXA5  POU2F2  POLR3D  FUZ  RCC1  EIF2S2  ITPR3  COMTD1  C16orf59  HMBS  RPS2  HSPA4L  PLEKHA1  ACTG2  RCC2  ARG2  MCM7  ZDHHC21  C12orf29  FAM120C  ASRGL1  NAPEPLD  CSRP2  B4GALT2  SYDE2  RGS16  TNFRSF21  MYB  MYBBP1A  TMEM177  PHC2  GATM  NAT8L  GRK5  STEAP1  COCH  SNHG7  RPL27A  GDF11  AEBP1  FRMD4A  CD22  BTBD16  FCRL5  OVOL2  TM7SF2  P2RY8  FAAH2  FLNB  FA2H  PODXL  GNB3  LEPREL2  CTDSP2  XBP1  LSS  ZDHHC23  TSPAN4  HSP90B1  CKAP4  CCL17  NPAS1  FCRL2  FCRL3  GGA2  CABLES1  PARD6A  EBF1  ELL2  RIMS3  KCNA3  TIMP2  IL12A  GEN1  MAN2A2  KHK  KBTBD11  HIP1R  ALOX5  ASMT  MMD  SLC6A16  SOBP  BIK  FCRL1  GSTP1  GUCY2C  TNFAIP2  IRAK3  SALL2  LRRC56  PDE4B  SH2D5  FJX1  VSNL1  VASH2  MOCOS  HSD17B6  LRRC8B  SEPHS1  DENND1A  C9orf24  SLC44A1  REEP2  DLL3  STAT3  CD1C  F12  TMEM18  SNAI3  PRDM2  KHDC1  TBC1D27  XRCC2  CALM1  MLXIP  IGL@  PCYOX1  THAP2  LRP5  AVIL  DERL3  MCM9  NUPL1  ELOVL6  MMAB  GADD45A  SCD  MVK  REPIN1  ZNF292  C1orf213  PSIP1  F11R  ACSL3  SPRED1  NHEDC2  KIAA1715  TMED2  CRTC3  RGPD1  TMEM135  IGHG1  PFKFB3  GHRL  TMEM151B  PAPOLG  TNS3  ACSS1  RASL10B  LGALS7  MGST3  ROPN1L  ACTL8  IRS2  FAM71E1  ST7  SLC4A7  SKP2  IL10  IDH3A  MYC  SRRM1  PFKFB4  ALDOC  HAGHL  SLC25A23  ANKZF1  ATP1A1  ENO1  CLN6  CD320  NME4  PODXL2  NT5DC2  PARVB  GAMT  MFSD10  CD81  NUP210  PAQR4  CHID1  MFSD3  DPAGT1  RAB11FIP4  C14orf1  PLTP  GYPC  FSTL3  METRN 
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Fig. S6. Altered function mutations of OCT
33
	B	cell	signatures	enriched	in	three	or	more	of	five	cell	lines	afterknockdown	of	OCT2.	
set1 set1.size set2 set2.size intersection pvalue enrichment Conf.Interval.dn
IRF4-5 75 OCT2Up_BJAB 521 17 7.48283E-12 8.64 4.99
NFkB-9 64 OCT2Up_Ly10 475 12 3.26423E-08 7.84 4.15
STAT3Up-2 93 OCT2Up_Ly10 475 15 5.48307E-09 6.74 3.85
IRF4Up-2 181 OCT2Up_BJAB 521 27 2.69607E-13 5.68 3.74
ABCDLBCL-3 58 OCT2Up_Ly10 475 10 1.04513E-06 7.20 3.62
NFkB-10 248 OCT2Up_Ly10 475 29 1.88708E-12 4.89 3.28
IRF4Up-3 301 OCT2Up_BJAB 521 34 8.54123E-13 4.30 2.98
IL10Up-1 122 OCT2Up_Ly10 475 15 2.29139E-07 5.14 2.97
BCRUp-2 119 OCT2Up_TMD8 364 11 1.22138E-05 5.04 2.69
TCF3Up-1 139 OCT2Up_HBL1 1329 35 5.17852E-12 3.76 2.55
RapaDn-2 128 OCT2Up_TMD8 364 11 2.43478E-05 4.69 2.50
MYD88Up-2 117 OCT2Up_TMD8 364 10 5.95724E-05 4.66 2.42
JAKUp-2 387 OCT2Up_TMD8 364 25 5.84551E-08 3.52 2.32
MYD88Up-1 324 OCT2Up_TMD8 364 21 6.48372E-07 3.53 2.24
PanB-2 136 OCT2Up_TMD8 364 10 0.000208929 4.01 2.09
CC-2 284 OCT2Up_Ly10 475 18 0.000180828 2.65 1.63
	B	cell	signatures	enriched	in	three	or	more	of	five	cell	lines	afterknockdown	of	OCT2.	
set1 set1.size set2 set2.size intersection pvalue enrichment Conf.Interval.dn
IRF4Up-2 181 OCA-BUp_HT 472 23 6.2446E-11 5.34 3.42
IRF4Up-3 301 OCA-BUp_HBL1 348 24 7.6219E-10 4.55 2.95
TCF3Up-1 139 OCA-BUp_HT 472 15 1.15852E-06 4.54 2.63
PC-2 347 OCA-BUp_Ly10 152 12 1.53414E-05 4.52 2.48
MYD88Up-1 324 OCA-BUp_BJAB 194 12 8.66395E-05 3.79 2.09
SerumDown 198 OCA-BUp_HT 472 14 0.000290479 2.97 1.71
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GO	terms	associated	with	genes	with	decreased	expression	in	Pou2f2	 knockout	murine	splenic	B	cells	stimulated	in	vitro
GO	biological	process	complete Mus	musculus	(REF) Overlap expected 	Fold	Enrichment P	value
toll-like	receptor	signaling	pathway 36 9 1.09 >	5 1.56E-02
positive	regulation	of	B	cell	proliferation 39 9 1.18 >	5 2.96E-02
regulation	of	B	cell	proliferation 59 12 1.78 >	5 2.86E-03
positive	regulation	of	B	cell	activation 67 12 2.03 >	5 1.06E-02
regulation	of	B	cell	activation 104 17 3.15 >	5 2.68E-04
immune	response-regulating	signaling	pathway 148 23 4.48 >	5 2.86E-06
positive	regulation	of	lymphocyte	proliferation 111 17 3.36 >	5 6.68E-04
positive	regulation	of	mononuclear	cell	proliferation 112 17 3.39 >	5 7.57E-04
regulation	of	production	of	molecular	mediator	of	immune	response88 13 2.66 4.88 3.13E-02
immune	response-regulating	cell	surface	receptor	signaling	pathway95 14 2.87 4.87 1.39E-02
positive	regulation	of	leukocyte	proliferation 116 17 3.51 4.85 1.23E-03
cellular	response	to	lipopolysaccharide 103 15 3.11 4.82 6.98E-03
immune	response-activating	signal	transduction 132 19 3.99 4.76 3.10E-04
cellular	response	to	molecule	of	bacterial	origin 112 16 3.39 4.72 3.92E-03
negative	regulation	of	protein	serine/threonine	kinase	activity109 15 3.3 4.55 1.38E-02
T	cell	differentiation 134 18 4.05 4.44 1.89E-03
cellular	response	to	biotic	stimulus 129 17 3.9 4.36 5.23E-03
regulation	of	lymphocyte	proliferation 179 23 5.41 4.25 9.56E-05
regulation	of	mononuclear	cell	proliferation 180 23 5.44 4.23 1.06E-04
negative	regulation	of	protein	kinase	activity 189 24 5.72 4.2 5.79E-05
negative	regulation	of	kinase	activity 205 26 6.2 4.19 1.42E-05
B	cell	activation 145 18 4.39 4.1 5.77E-03
regulation	of	leukocyte	proliferation 186 23 5.62 4.09 1.90E-04
negative	regulation	of	MAPK	cascade 130 16 3.93 4.07 2.60E-02
negative	regulation	of	transferase	activity 237 29 7.17 4.05 3.74E-06
regulation	of	lymphocyte	activation 319 39 9.65 4.04 3.93E-09
positive	regulation	of	lymphocyte	activation 197 24 5.96 4.03 1.25E-04
lymphocyte	differentiation 222 26 6.71 3.87 7.02E-05
leukocyte	activation 419 49 12.67 3.87 2.02E-11
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response	to	lipopolysaccharide 184 21 5.56 3.77 2.76E-03
activation	of	immune	response 176 20 5.32 3.76 5.55E-03
lymphocyte	activation 346 39 10.46 3.73 4.39E-08
response	to	molecule	of	bacterial	origin 201 22 6.08 3.62 2.93E-03
leukocyte	differentiation 302 33 9.13 3.61 4.06E-06
regulation	of	leukocyte	activation 376 41 11.37 3.61 3.45E-08
regulation	of	cell	activation 406 44 12.28 3.58 6.85E-09
positive	regulation	of	leukocyte	activation 224 24 6.77 3.54 1.29E-03
positive	regulation	of	cell	activation 235 25 7.11 3.52 8.16E-04
cell	activation 505 52 15.27 3.4 3.86E-10
regulation	of	MAP	kinase	activity 235 24 7.11 3.38 2.99E-03
negative	regulation	of	protein	phosphorylation 344 34 10.4 3.27 2.69E-05
T	cell	aggregation 234 23 7.08 3.25 9.79E-03
T	cell	activation 234 23 7.08 3.25 9.79E-03
negative	regulation	of	phosphorylation 369 36 11.16 3.23 1.30E-05
lymphocyte	aggregation 236 23 7.14 3.22 1.13E-02
regulation	of	protein	serine/threonine	kinase	activity 363 35 10.98 3.19 2.93E-05
leukocyte	aggregation 242 23 7.32 3.14 1.70E-02
positive	regulation	of	immune	response 317 30 9.59 3.13 5.62E-04
regulation	of	homotypic	cell-cell	adhesion 244 23 7.38 3.12 1.94E-02
leukocyte	cell-cell	adhesion 266 25 8.04 3.11 7.61E-03
immune	effector	process 341 32 10.31 3.1 2.51E-04
negative	regulation	of	immune	system	process 348 32 10.52 3.04 3.95E-04
regulation	of	immune	response 437 40 13.22 3.03 9.71E-06
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Supplementary	Table	3.		Sanger	Sequencing	of	POU2F2	POU	domain	in	207	DLBCL	biopsies	and	cell	lines
ID Subtype NT	change AA	change subtype POU	Mutated T223	Mutated
LY10 ABC WT WT ABC	(N=92) 8 3
OYB ABC WT WT GCB	(N=113) 4 4
PCNSL_TK ABC c.845G>A p.R282H unclass	(N=14) 0 0
Riva ABC c.1012C>T p.R338C DLBCL		(N=219) 12 8
SPECS104 ABC WT WT subtype %	Mutated %	T223	Mutated
SPECS1087 ABC WT WT ABC	(N=92) 8.70% 3.26%
SPECS1093 ABC WT WT GCB	(N=113) 3.54% 3.54%
SPECS1096 ABC WT WT unclass	(N=14) 0.00% 0.00%
SPECS1098 ABC WT WT DLBCL		(N=219) 5.48% 3.65%
SPECS1099 ABC c.865G>A p.E289K
SPECS1120 ABC c.994C>T p.R332W
SPECS114 ABC WT WT
SPECS1167 ABC c.973A>T p.I325F
SPECS1168 ABC WT WT
SPECS1175 ABC WT WT ID Subtype NT	change AA	change
SPECS1179 ABC WT WT Riva ABC c.1012C>T p.R338C
SPECS1186 ABC WT WT PCNSL_TK ABC c.845G>A p.R282H
SPECS1192 ABC WT WT SPECS1704 ABC c.667A>G p.T223A
SPECS1216 ABC WT WT SPECS97 ABC c.[667A>G];[667A>G] p.[T223A];[T223A]
SPECS1221 ABC WT WT SPECS1297 ABC c.667A>G p.T223A
SPECS1224 ABC WT WT SPECS1167 ABC c.973A>T p.I325F
SPECS1230 ABC WT WT SPECS1120 ABC c.994C>T p.R332W
SPECS1232 ABC WT WT SPECS1099 ABC c.865G>A p.E289K
SPECS1233 ABC WT WT SPECS2651 GCB c.667A>G p.T223A
SPECS1236 ABC WT WT SPECS1215 GCB c.667A>G p.T223A
SPECS1238 ABC WT WT SPECS1920 GCB c.667A>G p.T223A
SPECS1241 ABC WT WT SPECS2643 GCB c.667A>T p.T223S
SPECS1255 ABC WT WT
SPECS1272 ABC WT WT
SPECS1275 ABC WT WT
SPECS1279 ABC WT WT
SPECS1288 ABC WT WT
SPECS1289 ABC WT WT
SPECS1292 ABC WT WT
SPECS1297 ABC c.667A>G p.T223A
SPECS1298 ABC WT WT
SPECS1335 ABC WT WT
SPECS1450 ABC WT WT
SPECS1619 ABC WT WT
SPECS1623 ABC WT WT
SPECS1628 ABC WT WT
SPECS1650 ABC WT WT
SPECS1651 ABC WT WT
SPECS1702 ABC WT WT
SPECS1702 ABC WT WT
SPECS1703 ABC WT WT
SPECS1704 ABC c.667A>G p.T223A
SPECS1705 ABC WT WT
SPECS1745 ABC WT WT
SPECS1746 ABC WT WT
SPECS1747 ABC WT WT
SPECS1747 ABC WT WT
SPECS1928 ABC WT WT
SPECS1939 ABC WT WT
SPECS1939 ABC WT WT
SPECS2 ABC WT WT
SPECS2002 ABC WT WT
SPECS22 ABC WT WT
SPECS2274 ABC WT WT
SPECS2274 ABC WT WT
SPECS2283 ABC WT WT
SPECS2306 ABC WT WT
SPECS2306 ABC WT WT
SPECS2321 ABC WT WT
SPECS2411 ABC WT WT
SPECS2415 ABC WT WT
SPECS2445 ABC WT WT
SPECS2488 ABC WT WT
SPECS2501 ABC WT WT
SPECS2503 ABC WT WT
SPECS2504 ABC WT WT
SPECS2507 ABC WT WT
SPECS2508 ABC WT WT
SPECS2509 ABC WT WT
SPECS2511 ABC WT WT
SPECS2517 ABC WT WT
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SPECS2600 ABC WT WT
SPECS2601 ABC WT WT
SPECS2612 ABC WT WT
SPECS2614 ABC WT WT
SPECS2635 ABC WT WT
SPECS2641 ABC WT WT
SPECS2648 ABC WT WT
SPECS3633 ABC WT WT
SPECS41 ABC WT WT
SPECS41 ABC WT WT
SPECS47 ABC WT WT
SPECS47 ABC WT WT
SPECS48 ABC WT WT
SPECS48 ABC WT WT
SPECS97 ABC c.667A>G p.T223A
SPECS98 ABC WT WT
SUDHL2 ABC WT WT
U2932 ABC WT WT
BJAB GCB WT WT
DLBCL2 GCB WT WT
HT GCB WT WT
Karpas422 GCB WT WT
LY18 GCB WT WT
LY19 GCB WT WT
Ly7 GCB WT WT
Ly8 GCB WT WT
NUDUL1 GCB WT WT
Pfeiffer GCB WT WT
SPECS107 GCB WT WT
SPECS1091 GCB WT WT
SPECS1097 GCB WT WT
SPECS111 GCB WT WT
SPECS1169 GCB WT WT
SPECS1172 GCB WT WT
SPECS1173 GCB WT WT
SPECS118 GCB WT WT
SPECS1181 GCB WT WT
SPECS1184 GCB WT WT
SPECS1187 GCB WT WT
SPECS1189 GCB WT WT
SPECS119 GCB WT WT
SPECS1190 GCB WT WT
SPECS1190 GCB WT WT
SPECS1195 GCB WT WT
SPECS1197 GCB WT WT
SPECS1215 GCB c.667A>G p.T223A
SPECS1222 GCB WT WT
SPECS1228 GCB WT WT
SPECS1231 GCB WT WT
SPECS1252 GCB WT WT
SPECS1271 GCB WT WT
SPECS1277 GCB WT WT
SPECS1284 GCB WT WT
SPECS1290 GCB WT WT
SPECS1291 GCB WT WT
SPECS1293 GCB WT WT
SPECS1294 GCB WT WT
SPECS1331 GCB WT WT
SPECS1334 GCB WT WT
SPECS1336 GCB WT WT
SPECS1451 GCB WT WT
SPECS1453 GCB WT WT
SPECS1454 GCB WT WT
SPECS1612 GCB WT WT
SPECS1613 GCB WT WT
SPECS1614 GCB WT WT
SPECS1617 GCB WT WT
SPECS1620 GCB WT WT
SPECS1626 GCB WT WT
SPECS1647 GCB WT WT
SPECS1707 GCB WT WT
SPECS1782 GCB WT WT
SPECS1782 GCB WT WT
SPECS1861 GCB WT WT
SPECS1916 GCB WT WT
SPECS1920 GCB c.667A>G p.T223A
SPECS2006 GCB WT WT
SPECS2067 GCB WT WT
SPECS2070 GCB WT WT
SPECS2070 GCB WT WT
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SPECS21 GCB WT WT
SPECS2162 GCB WT WT
SPECS2270 GCB WT WT
SPECS2270 GCB WT WT
SPECS2291 GCB WT WT
SPECS2299 GCB WT WT
SPECS2299 GCB WT WT
SPECS23 GCB WT WT
SPECS2309 GCB WT WT
SPECS2311 GCB WT WT
SPECS2318 GCB WT WT
SPECS24 GCB WT WT
SPECS2479 GCB WT WT
SPECS2482 GCB WT WT
SPECS2486 GCB WT WT
SPECS2487 GCB WT WT
SPECS2490 GCB WT WT
SPECS2500 GCB WT WT
SPECS2512 GCB WT WT
SPECS2513 GCB WT WT
SPECS2514 GCB WT WT
SPECS2516 GCB WT WT
SPECS2584 GCB WT WT
SPECS2599 GCB WT WT
SPECS2604 GCB WT WT
SPECS2610 GCB WT WT
SPECS2611 GCB WT WT
SPECS2613 GCB WT WT
SPECS2615 GCB WT WT
SPECS2639 GCB WT WT
SPECS2642 GCB WT WT
SPECS2643 GCB c.667A>T p.T223S
SPECS2645 GCB WT WT
SPECS2649 GCB WT WT
SPECS2650 GCB WT WT
SPECS2651 GCB c.667A>G p.T223A
SPECS2652 GCB WT WT
SPECS2653 GCB WT WT
SPECS28 GCB WT WT
SPECS3 GCB WT WT
SPECS3631 GCB WT WT
SPECS3635 GCB WT WT
SPECS49 GCB WT WT
SPECS53 GCB WT WT
SPECS96 GCB WT WT
SUDHL10 GCB WT WT
SUDHL4 GCB WT WT
SUDHL5 GCB WT WT
SUDHL7 GCB WT WT
SUDHL8 GCB WT WT
WSDLBCL2 GCB WT WT
SPECS1742 Unclass WT WT
SPECS1927 Unclass WT WT
SPECS2301 Unclass WT WT
SPECS2444 Unclass WT WT
SPECS2483 Unclass WT WT
SPECS2485 Unclass WT WT
SPECS2492 Unclass WT WT
SPECS2497 Unclass WT WT
SPECS2498 Unclass WT WT
SPECS2505 Unclass WT WT
SPECS2515 Unclass WT WT
SPECS2603 Unclass WT WT
SPECS2609 Unclass WT WT





set1 set1.size set2 set2.size intersection pvalue enrichment Conf.Interval.dn
AMIT_SERUM_RESPONSE_60_MCF10A 57 Up_T223A_HBL1 642 12 3.33741E-08 7.76 4.08
GAJATE_RESPONSE_TO_TRABECTEDIN_UP 52 Up_T223A_HBL1 642 11 1.1866E-07 7.79 3.99
SHAFFER_IRF4_TARGETS_IN_PLASMA_CELL_VS_MATURE_B_LYMPHOCYTE 66 Up_T223A_HBL1 642 13 2.09514E-08 7.26 3.94
GUTIERREZ_CHRONIC_LYMPHOCYTIC_LEUKEMIA_DN 54 Up_T223A_HBL1 642 11 1.79011E-07 7.51 3.85
BASSO_CD40_SIGNALING_UP 101 Up_T223A_HBL1 642 17 1.8308E-09 6.20 3.66
BILBAN_B_CLL_LPL_UP 59 Up_T223A_HBL1 642 11 4.62822E-07 6.87 3.55
SHAFFER_IRF4_TARGETS_IN_MYELOMA_VS_MATURE_B_LYMPHOCYTE 96 Up_T223A_HBL1 642 15 4.64954E-08 5.76 3.30
ELVIDGE_HYPOXIA_BY_DMOG_UP 127 Up_T223A_HBL1 642 18 1.04573E-08 5.22 3.15
ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN 101 Up_T223A_HBL1 642 15 9.33125E-08 5.47 3.14
ELVIDGE_HYPOXIA_UP 165 Up_T223A_HBL1 642 22 8.05047E-10 4.91 3.11
WILCOX_PRESPONSE_TO_ROGESTERONE_UP 146 Up_T223A_HBL1 642 19 1.71585E-08 4.80 2.94
RUIZ_TNC_TARGETS_UP 149 Up_T223A_HBL1 642 19 2.40224E-08 4.70 2.88
KIM_WT1_TARGETS_UP 210 Up_T223A_HBL1 642 25 6.54361E-10 4.39 2.87
PODAR_RESPONSE_TO_ADAPHOSTIN_UP 141 Up_T223A_HBL1 642 18 5.50381E-08 4.70 2.85
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP 66 Up_T223A_HBL1 642 10 1.08411E-05 5.58 2.84
HOEBEKE_LYMPHOID_STEM_CELL_DN 85 Up_T223A_HBL1 642 12 3.10753E-06 5.20 2.81
MENSE_HYPOXIA_UP 97 Up_T223A_HBL1 642 13 2.21166E-06 4.94 2.74
ODONNELL_TARGETS_OF_MYC_AND_TFRC_UP 78 Up_T223A_HBL1 642 11 8.06922E-06 5.20 2.73
RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP 332 Up_T223A_HBL1 642 35 8.37064E-12 3.88 2.71
NAGASHIMA_NRG1_SIGNALING_UP 170 Up_T223A_HBL1 642 20 4.09896E-08 4.34 2.70
MISSIAGLIA_REGULATED_BY_METHYLATION_UP 99 Up_T223A_HBL1 642 13 2.79344E-06 4.84 2.69
RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_DN 241 Up_T223A_HBL1 642 26 2.52152E-09 3.98 2.63
HUTTMANN_B_CLL_POOR_SURVIVAL_UP 265 Up_T223A_HBL1 642 28 9.8919E-10 3.89 2.61
UDAYAKUMAR_MED1_TARGETS_DN 235 Up_T223A_HBL1 642 25 6.8018E-09 3.92 2.57
LINDGREN_BLADDER_CANCER_CLUSTER_2B 381 Up_T223A_HBL1 642 36 9.70997E-11 3.48 2.45
OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_DN 224 Up_T223A_HBL1 642 23 5.27979E-08 3.78 2.44
OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_UP 224 Up_T223A_HBL1 642 23 5.27979E-08 3.78 2.44
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP 156 Up_T223A_HBL1 642 17 1.25506E-06 4.02 2.41
TAKAO_RESPONSE_TO_UVB_RADIATION_DN 90 Up_T223A_HBL1 642 11 3.21751E-05 4.50 2.39
CONCANNON_APOPTOSIS_BY_EPOXOMICIN_UP 233 Up_T223A_HBL1 642 23 1.08982E-07 3.64 2.35
HORIUCHI_WTAP_TARGETS_UP 283 Up_T223A_HBL1 642 27 1.78065E-08 3.52 2.35
PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_DN 128 Up_T223A_HBL1 642 14 1.03141E-05 4.03 2.30
KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP 733 Up_T223A_HBL1 642 60 2.87036E-14 3.02 2.29
DANG_REGULATED_BY_MYC_DN 240 Up_T223A_HBL1 642 23 1.86516E-07 3.53 2.28
RUTELLA_RESPONSE_TO_HGF_UP 410 Up_T223A_HBL1 642 36 7.37761E-10 3.24 2.28
ZHONG_RESPONSE_TO_AZACITIDINE_AND_TSA_UP 180 Up_T223A_HBL1 642 18 2.15691E-06 3.68 2.25
OKUMURA_INFLAMMATORY_RESPONSE_LPS 181 Up_T223A_HBL1 642 18 2.33567E-06 3.66 2.24
LEE_RECENT_THYMIC_EMIGRANT 97 Up_T223A_HBL1 642 11 6.48333E-05 4.18 2.22
ONDER_CDH1_TARGETS_2_UP 249 Up_T223A_HBL1 642 23 3.60659E-07 3.40 2.20
ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_UP 213 Up_T223A_HBL1 642 20 1.60407E-06 3.46 2.17
REN_ALVEOLAR_RHABDOMYOSARCOMA_DN 404 Up_T223A_HBL1 642 34 6.47769E-09 3.10 2.16
ELVIDGE_HIF1A_TARGETS_DN 88 Up_T223A_HBL1 642 10 0.000135975 4.19 2.16
CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_UP 163 Up_T223A_HBL1 642 16 9.94905E-06 3.62 2.15
SASAKI_ADULT_T_CELL_LEUKEMIA 138 Up_T223A_HBL1 642 14 2.43815E-05 3.74 2.14
VERHAAK_AML_WITH_NPM1_MUTATED_UP 178 Up_T223A_HBL1 642 17 7.64424E-06 3.52 2.12
KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN 306 Up_T223A_HBL1 642 26 3.26627E-07 3.13 2.08
ENK_UV_RESPONSE_EPIDERMIS_DN 501 Up_T223A_HBL1 642 39 4.49706E-09 2.87 2.05
MITSIADES_RESPONSE_TO_APLIDIN_UP 427 Up_T223A_HBL1 642 34 2.5658E-08 2.93 2.05
ODONNELL_TFRC_TARGETS_UP 398 Up_T223A_HBL1 642 32 5.28436E-08 2.96 2.05
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP 341 Up_T223A_HBL1 642 28 2.34345E-07 3.03 2.04
RIGGINS_TAMOXIFEN_RESISTANCE_DN 216 Up_T223A_HBL1 642 19 7.55131E-06 3.24 2.01
Supplementary	Table	4B.		Enrichment	analysis	of	Broad	Institute	molecular	signatures	amongst	genes	with	enhanced	or	reduced	expression	
(measured	by	RNA-seq)	in	human	DLBCL	biopsies	from	tumours	with	T223A	mutated	OCT2	compared	to	cases	with	wild	type	OCT2.
set1 set1.size set2 set2.size intersection pvalue enrichment Conf.Interval.dn
HUPER_BREAST_BASAL_VS_LUMINAL_UP 54 UP.in.T223A.patients 704 16 2.35403E-12 9.96 5.52
RICKMAN_HEAD_AND_NECK_CANCER_E 86 UP.in.T223A.patients 704 22 5.39905E-15 8.60 5.26
ELVIDGE_HIF1A_TARGETS_DN 88 UP.in.T223A.patients 704 18 9.33304E-11 6.87 4.07
LIN_SILENCED_BY_TUMOR_MICROENVIRONMENT 102 UP.in.T223A.patients 704 17 8.44227E-09 5.60 3.31
ONDER_CDH1_TARGETS_3_DN 52 UP.in.T223A.patients 704 10 2.61267E-06 6.46 3.23
ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN 101 UP.in.T223A.patients 704 16 4.86445E-08 5.32 3.10
ELVIDGE_HYPOXIA_BY_DMOG_UP 127 UP.in.T223A.patients 704 17 2.34974E-07 4.50 2.68
JAEGER_METASTASIS_DN 256 UP.in.T223A.patients 704 30 1.77771E-10 3.94 2.67
SABATES_COLORECTAL_ADENOMA_UP 128 UP.in.T223A.patients 704 16 1.34882E-06 4.20 2.47
ELVIDGE_HYPOXIA_UP 165 UP.in.T223A.patients 704 19 5.12629E-07 3.87 2.38
RICKMAN_HEAD_AND_NECK_CANCER_C 105 UP.in.T223A.patients 704 13 1.45124E-05 4.16 2.32
HARRIS_HYPOXIA 78 UP.in.T223A.patients 704 10 0.000103745 4.31 2.21
ONDER_CDH1_TARGETS_2_DN 458 UP.in.T223A.patients 704 41 4.27904E-10 3.01 2.16
WINTER_HYPOXIA_METAGENE 215 UP.in.T223A.patients 704 21 2.01143E-06 3.28 2.08
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_DN 166 UP.in.T223A.patients 704 17 9.98444E-06 3.44 2.07
MENSE_HYPOXIA_UP 97 UP.in.T223A.patients 704 11 0.000146205 3.81 2.03




set1 set1.size set2 set2.size intersection pvalue enrichment Conf.Interval.dn
IRF4-5 78 Dn_T223A_BJAB 665 11 1.12203E-05 5.02 2.64
Common_OCT2_UP 388 Dn_T223A_BJAB 665 52 7.04356E-21 4.77 3.52
TCF3Up-1 132 Dn_T223A_BJAB 665 17 1.85704E-07 4.58 2.74
StarveUp-2 120 Dn_T223A_BJAB 665 15 1.42774E-06 4.45 2.57
Common_OCA-B_UP 127 Dn_T223A_BJAB 665 15 2.93809E-06 4.20 2.44
IRF4Up-2 187 Dn_T223A_BJAB 665 19 1.49457E-06 3.61 2.23
StarveUp-1 288 Dn_T223A_BJAB 665 29 3.38806E-09 3.58 2.42
TActUp-1 130 Dn_T223A_BJAB 665 13 7.83055E-05 3.56 2.00
IRF4Up-3 309 Dn_T223A_BJAB 665 30 4.28532E-09 3.45 2.35
MYD88Up-1 313 Dn_T223A_BJAB 665 28 8.12391E-08 3.18 2.14
BioChIP_BJAB_Reduced_T223A	vs	WT_OCT2 539 Dn_T223A_BJAB 665 42 3.10819E-09 2.77 2.00
MYD88Up-4 36 Dn_T223A_HBL 752 10 1.1928E-07 8.74 4.20
STAT3Up-1 41 Dn_T223A_HBL 752 11 4.11897E-08 8.44 4.21
Blimp-1 65 Dn_T223A_HBL 752 17 1.29624E-11 8.23 4.71
JAK2Up-2 54 Dn_T223A_HBL 752 13 1.01616E-08 7.57 4.04
Module-1.3 68 Dn_T223A_HBL 752 14 2.39708E-08 6.48 3.58
Module-3.1 115 Dn_T223A_HBL 752 22 1.15176E-11 6.02 3.76
IFN-2 92 Dn_T223A_HBL 752 17 4.38836E-09 5.81 3.42
IL10Up-1 123 Dn_T223A_HBL 752 22 4.62011E-11 5.63 3.53
Common_OCT2_UP 388 Dn_T223A_HBL 752 64 1.12662E-27 5.19 3.93
IFN-1 153 Dn_T223A_HBL 752 25 1.75477E-11 5.14 3.33
NFkB-9 65 Dn_T223A_HBL 752 10 3.65758E-05 4.84 2.46
NFkB-1 67 Dn_T223A_HBL 752 10 4.78573E-05 4.70 2.39
PanB-3 97 Dn_T223A_HBL 752 14 2.32319E-06 4.54 2.57
TCF3Dn-1 161 Dn_T223A_HBL 752 23 1.7412E-09 4.49 2.87
IFN-3 316 Dn_T223A_HBL 752 45 3.19225E-17 4.48 3.24
KLF2Up-1 108 Dn_T223A_HBL 752 14 8.41408E-06 4.08 2.31
PanB-2 134 Dn_T223A_HBL 752 16 5.75348E-06 3.76 2.22
Module-3.1 115 Up_T223A_BJAB 777 50 2.21991E-43 13.24 9.09
MYD88Up-4 36 Up_T223A_BJAB 777 14 2.94064E-12 11.84 6.03
IFN-2 92 Up_T223A_BJAB 777 32 1.58387E-24 10.59 6.85
MZB-2 38 Up_T223A_BJAB 777 12 1.78867E-09 9.61 4.83
IFN-1 153 Up_T223A_BJAB 777 45 2.24235E-30 8.95 6.28
MM-6 45 Up_T223A_BJAB 777 12 1.53815E-08 8.12 4.18
TCF3Dn-1 161 Up_T223A_BJAB 777 40 4.60066E-24 7.56 5.25
IFN-3 316 Up_T223A_BJAB 777 74 9.44011E-42 7.13 5.44
MM-9 43 Up_T223A_BJAB 777 10 9.89712E-07 7.08 3.48
MZB-1 69 Up_T223A_BJAB 777 15 5.31457E-09 6.62 3.72
Blimp-1 65 Up_T223A_BJAB 777 14 1.95303E-08 6.56 3.61
Heme-1 98 Up_T223A_BJAB 777 20 5.15285E-11 6.21 3.78
Common_OCA-B_DN 343 Up_T223A_BJAB 777 69 1.76781E-34 6.12 4.66
Common_OCT2_DN 568 Up_T223A_BJAB 777 113 6.30611E-56 6.06 4.86
NFkB-1 67 Up_T223A_BJAB 777 13 2.31214E-07 5.91 3.21
TActDn-4 59 Up_T223A_BJAB 777 11 2.96895E-06 5.68 2.94
PAX5-1 66 Up_T223A_BJAB 777 12 1.3991E-06 5.54 2.95
Module-1.3 68 Up_T223A_BJAB 777 12 1.94888E-06 5.37 2.87
PanB-3 97 Up_T223A_BJAB 777 17 1.63939E-08 5.34 3.15
NFkB-9 65 Up_T223A_BJAB 777 11 7.93874E-06 5.15 2.68
IRF3-1 166 Up_T223A_BJAB 777 28 1.05085E-12 5.14 3.40
PMBL-1 68 Up_T223A_BJAB 777 11 1.24343E-05 4.93 2.57
MYD88Dn-1 307 Up_T223A_BJAB 777 43 9.71831E-16 4.26 3.06
Quiesce-2 182 Up_T223A_BJAB 777 25 1.5546E-09 4.18 2.73
CD40Up-1 134 Up_T223A_BJAB 777 18 4.21308E-07 4.09 2.48
IL10Up-1 123 Up_T223A_BJAB 777 16 2.81801E-06 3.96 2.33
Tdiff-6 139 Up_T223A_BJAB 777 18 7.31056E-07 3.94 2.39
PanB-2 134 Up_T223A_BJAB 777 17 1.97323E-06 3.86 2.31
CC-1 147 Up_T223A_BJAB 777 18 1.67235E-06 3.73 2.26
TCF3Up-1 132 Up_T223A_BJAB 777 16 7.13028E-06 3.69 2.18
JAK2Dn-1 410 Up_T223A_BJAB 777 49 5.84088E-15 3.64 2.68
IRF4-6 67 Up_T223A_HBL1 642 13 2.53566E-08 7.15 3.88
PMBL-1 68 Up_T223A_HBL1 642 13 3.05798E-08 7.04 3.83
NFkB-9 65 Up_T223A_HBL1 642 11 1.27727E-06 6.24 3.25
NFkB-1 67 Up_T223A_HBL1 642 11 1.7459E-06 6.05 3.15
Common_OCT2_DN 568 Up_T223A_HBL1 642 82 5.19639E-36 5.32 4.15
BCRUp-2 119 Up_T223A_HBL1 642 17 2.37266E-08 5.26 3.13
KRASUp-1 83 Up_T223A_HBL1 642 11 1.48149E-05 4.88 2.58
CD40Up-1 134 Up_T223A_HBL1 642 17 1.40889E-07 4.67 2.79
CC-1 147 Up_T223A_HBL1 642 17 5.40779E-07 4.26 2.55
Common_OCA-B_DN 343 Up_T223A_HBL1 642 39 4.60287E-14 4.19 2.97
Tdiff-5 106 Up_T223A_HBL1 642 12 3.09945E-05 4.17 2.28
IRF4Up-2 187 Up_T223A_HBL1 642 21 4.2765E-08 4.14 2.61
JAK2Dn-1 410 Up_T223A_HBL1 642 43 3.91163E-14 3.86 2.79
PC-2 341 Up_T223A_HBL1 642 35 1.78656E-11 3.78 2.64
ABCDLBCL-4 387 Up_T223A_HBL1 642 38 9.1946E-12 3.62 2.56
IRF4Up-3 309 Up_T223A_HBL1 642 29 7.6554E-09 3.46 2.34
SerumDown 198 Up_T223A_HBL1 642 18 8.28713E-06 3.35 2.05
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